Abstract

The androgen receptor (AR) is a member of the nuclear receptor superfamily of transcription factors and is central to prostate cancer (PCa) progression. Ligand-activated AR engages androgen response elements (AREs) at androgen-responsive genes to drive the expression of gene batteries involved in cell proliferation and cell fate. Understanding the transcriptional targets of the AR has become critical in apprehending the mechanisms driving treatment-resistant stages of PCa. Although AR transcription regulation has been extensively studied, the signaling networks downstream of AR are incompletely described. Semaphorin 3C (SEMA3C) is a secreted signaling protein with roles in nervous system and cardiac development but can also drive cellular growth and invasive characteristics in multiple cancers including PCa. Despite numerous findings that implicate SEMA3C in cancer progression, regulatory mechanisms governing its expression remain largely unknown. Here we identify and characterize an androgen response element within the SEMA3C locus. Using the AR-positive LNCaP PCa cell line, we show that SEMA3C expression is driven by AR through this element and that AR-mediated expression of SEMA3C is dependent on the transcription factor GATA2. SEMA3C has been shown to promote cellular growth in certain cell types so implicit to our findings is the discovery of direct regulation of a growth factor by AR. We also show that FOXA1 is a negative regulator of SEMA3C. These findings identify SEMA3C as a novel target of AR, GATA2, and FOXA1 and expand our understanding of semaphorin signaling and cancer biology.

Highlights

  • The androgen receptor (AR) is a 110 kDa member of the nuclear hormone receptor (NR) superfamily of transcription factors

  • We show that FOXA1 is a negative regulator of Semaphorin 3C (SEMA3C)

  • We show that GATA2 is a necessary coactivator of AR-mediated expression of SEMA3C and that FOXA1 is a negative regulator of SEMA3C

Read more

Summary

Introduction

The androgen receptor (AR) is a 110 kDa member of the nuclear hormone receptor (NR) superfamily of transcription factors. CRPC is often marked by: retention or amplification of the AR, biochemical recurrence of AR target genes such as prostate-specific antigen (PSA), and mutations to the AR rendering it constitutively active and refractory to the actions of antiandrogens [3]. These observations suggest a causal role for AR in disease progression and underscore the importance of AR blockade and identification of novel AR targets whose expression by AR facilitate disease progression

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call